GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rakovina Therapeutics Inc (TSXV:RKV) » Definitions » Beta

Rakovina Therapeutics (TSXV:RKV) Beta : 0.23 (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rakovina Therapeutics Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-06-19), Rakovina Therapeutics's Beta is 0.23.


Rakovina Therapeutics Beta Historical Data

The historical data trend for Rakovina Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rakovina Therapeutics Beta Chart

Rakovina Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Beta
- - -

Rakovina Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.16

Competitive Comparison of Rakovina Therapeutics's Beta

For the Biotechnology subindustry, Rakovina Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rakovina Therapeutics's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rakovina Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Rakovina Therapeutics's Beta falls into.



Rakovina Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Rakovina Therapeutics  (TSXV:RKV) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Rakovina Therapeutics Beta Related Terms

Thank you for viewing the detailed overview of Rakovina Therapeutics's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Rakovina Therapeutics (TSXV:RKV) Business Description

Traded in Other Exchanges
Address
8 Smithe Mews, Suite 2201, Vancouver, BC, CAN, V6B 0A5
Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA Damaging DDR-inhibitors.
Executives
Alfredo De Lucrezia Director, Senior Officer

Rakovina Therapeutics (TSXV:RKV) Headlines

No Headlines